SCHEMBL23975679

SCHEMBL23975679

Clc1nc2c(c(N3CCCCCC3)n1)CCC2

nearest known ligand 0.44

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.41
ALDH1A1 P00352 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
GBA1 P04062 3/20 0.40
ACHE P22303 2/20 0.38
APP P05067 1/20 0.38
BCHE P06276 1/20 0.38
HRH4 Q9H3N8 2/20 0.38
HTR2C P28335 1/20 0.38
PDE10A Q9Y233 1/20 0.37
CHRM3 P20309 2/20 0.37
PDE4A P27815 2/20 0.37
PDE4B Q07343 2/20 0.37
PDE4C Q08493 2/20 0.37
PDE4D Q08499 2/20 0.37
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30225185 1.00 HPGD (0.41) HPGDALDH1A1SMN1; SMN2GBA1ACHE
SCHEMBL25529505 0.95 HPGD (0.42) HPGDALDH1A1SMN1; SMN2GBA1ACHE
SCHEMBL2266744 0.85 ALDH1A1 (0.51) HPGDALDH1A1SMN1; SMN2ACHEAPP
SCHEMBL23975658 0.84 ALDH1A1 (0.48) HPGDALDH1A1SMN1; SMN2ACHEAPP
SCHEMBL30225319 0.84 ALDH1A1 (0.48) HPGDALDH1A1SMN1; SMN2ACHEAPP
SCHEMBL26650736 0.82 HRH4 (0.34) ALDH1A1GBA1HRH4HTR2CCHRM3
SCHEMBL23975932 0.78 HPGD (0.39) HPGDALDH1A1ACHEAPPBCHE
SCHEMBL23976724 0.77 KDM4E (0.40) HPGDALDH1A1SMN1; SMN2GBA1HRH4
SCHEMBL12655049 0.76 HRH4 (0.42) ALDH1A1SMN1; SMN2HRH4HTR2CPDE10A
SCHEMBL5734419 0.76 MEN1 (0.42) GBA1ACHEAPPBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-09-05 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2023-07-20 US disclosed
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2022-12-15 US disclosed
WO-2021222363-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed
WO-2021222483-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226074-A1 METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS SLC40A1, HAMP, SLC19A1 HPGD 217/4885ALDH1A1 918/4885SMN1; SMN2 1602/4885
US-11746100-B2 Cycloalkyl pyrimidines as ferroportin inhibitors HAMP, SLC40A1, FANCI HPGD 245/4885ALDH1A1 1674/4885SMN1; SMN2 2512/4885
US-20220396562-A1 CYCLOALKYL PYRIMIDINES AS FERROPORTIN INHIBITORS HAMP, SLC40A1, FANCI HPGD 245/4885ALDH1A1 1674/4885SMN1; SMN2 2512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.